1. Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.
- Author
-
McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Ueno NT, Ferrarotto R, Chang JT, and Lin SY
- Subjects
- Humans, Immune Checkpoint Inhibitors, Mutation, Biomarkers, Tumor genetics, Neoplasms drug therapy, Neoplasms pathology, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy
- Abstract
Competing Interests: Disclosures MKh has served as a consultant or advisory roles for Janssen, AbbVie, Ipsen, Pfizer, Roche, and Jackson Laboratory for Genomic Medicine and received research funding from AbbVie, Bristol Myers Squibb (BMS), and Specialized Therapeutics. ABH has stock options and is an advisory board member of Caris Life Sciences. ABH also serves on the advisory board of WCG Oncology, has received licensing fees from Celldex Therapeutics and DNAtrix, and received research funding from Merck. NTU has received research funding from Merck. MKo has advisory role for BMS, Roche, MSD, and Daiichi Sankyo, and the institute receives research funding from AstraZeneca, BMS, and Roche outside the submitted work. DJM, PGP, EJ, and SYL have a pending patent on a gene expression signature to predict response to immune checkpoint blockade. All other authors have declared no conflicts of interest.
- Published
- 2022
- Full Text
- View/download PDF